5 min listen
Antipsychotics and dementia risk; biomarkers for lecanemab eligibility; trial of difelikefalin for neurogenic itch in notaliga paresthetica.
Antipsychotics and dementia risk; biomarkers for lecanemab eligibility; trial of difelikefalin for neurogenic itch in notaliga paresthetica.
ratings:
Length:
6 minutes
Released:
Mar 16, 2023
Format:
Podcast episode
Description
In this week’s podcast, Neurology Today’s editor-in-chief discusses the increased use of antipsychotics during the pandemic and an associated greater risk for dementia, determining the best biomarkers when considering lecanemab for Alzheimer’s, and a novel approach for managing uncomfortable neuropathic symptoms.
Released:
Mar 16, 2023
Format:
Podcast episode
Titles in the series (99)
April 2, 2020 Issue Introduction by Neurology Today in 5